Ferroptosis-centered Disease Response Information

General Information of the Disease (ID: DIS00003)
Name
Chronic hepatitis C
ICD
ICD-11: 1E51
Full List of Target(s) of This Ferroptosis-centered Disease
Unspecific Target
In total 1 item(s) under this target
Experiment 1 Reporting the Ferroptosis-centered Disease Response by This Target [1]
Responsed Disease Hepatitis C [ICD-11: 1E51]
Responsed Regulator Acyl-CoA 6-desaturase (FADS2) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model Huh-7.5 cells Hepatocellular carcinoma Homo sapiens CVCL_7927
HEK293 FT cells Normal Homo sapiens CVCL_6911
PH5CH8 cells Normal Homo sapiens CVCL_VL00
A-549 cells Lung adenocarcinoma Homo sapiens CVCL_0023
In Vivo Model
Chimeric mice were purchased from PhoenixBio Co. (Hiroshima, Japan). The chimeric mice were generated by transplanting human primary hepatocytes into severe combined immunodeficient mice (3-week-old male) carrying the urokinase plasminogen activator transgene under control of an albumin promoter (Alb-uPA).

    Click to Show/Hide
Response regulation Inhibiting FADS2 markedly enhances hepatitis C virus (HCV) replication, whereas the ferroptosis-inducing compound erastin alters conformation of the HCV replicase and sensitizes it to direct-acting antiviral agents targeting the viral protease. Collectively, these data establish FADS2 as an important pro-ferroptotic factor that also restricts HCV replication.
References
Ref 1 FADS2-dependent fatty acid desaturation dictates cellular sensitivity to ferroptosis and permissiveness for hepatitis C virus replication. Cell Chem Biol. 2022 May 19;29(5):799-810.e4. doi: 10.1016/j.chembiol.2021.07.022. Epub 2021 Sep 13.